Stock Scorecard



Stock Summary for Tiziana Life Sciences Ltd (TLSA) - $1.57 as of 5/8/2025 11:58:10 AM EST

Total Score

9 out of 30

Safety Score

22 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for TLSA

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for TLSA

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for TLSA

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for TLSA

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for TLSA (22 out of 100)

Stock Price Rating (Max of 10) 2
Historical Stock Price Rating (Max of 10) 1
Stock Price Trend (Max of 10) 9
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for TLSA

Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis - Tiziana Life Sciences ( NASDAQ:TLSA ) 5/6/2025 11:00:00 AM
Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial - Tiziana Life Sciences ( NASDAQ:TLSA ) 4/23/2025 11:00:00 AM
Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial - Tiziana Life Sciences ( NASDAQ:TLSA ) 4/2/2025 12:00:00 PM
Tiziana Life Sciences to Present at the 37th Annual Roth Conference - Tiziana Life Sciences ( NASDAQ:TLSA ) 3/17/2025 12:00:00 PM
Tiziana Life Sciences to Present at the 37th Annual Roth Conference 3/17/2025 12:00:00 PM
Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC 2/21/2025 1:00:00 PM
Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer's Disease 2/11/2025 2:15:00 PM
Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3 1/23/2025 8:00:00 PM
Tiziana Life Confirms Discovery In Multiple Sclerosis Therapy Study - Tiziana Life Sciences ( NASDAQ:TLSA ) 1/23/2025 3:55:00 PM
Tiziana Life Sciences not to engage in capital raising activities for the immediate future 1/23/2025 1:54:00 PM

Financial Details for TLSA

Company Overview

Ticker TLSA
Company Name Tiziana Life Sciences Ltd
Country USA
Description Tiziana Life Sciences Plc, a clinical-stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the UK.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 6/30/2023
Next Earnings Date N/A

Stock Price History

Last Day Price 1.57
Price 4 Years Ago 0.96
Last Day Price Updated 5/8/2025 11:58:10 AM EST
Last Day Volume 1,023,358
Average Daily Volume 370,611
52-Week High 1.91
52-Week Low 0.56
Last Price to 52 Week Low 180.36%

Valuation Measures

Trailing PE N/A
Industry PE 30.37
Sector PE 45.26
5-Year Average PE -5.58
Free Cash Flow Ratio 157.00
Industry Free Cash Flow Ratio 18.71
Sector Free Cash Flow Ratio 29.93
Current Ratio Most Recent Quarter 1.12
Total Cash Per Share 0.01
Book Value Per Share Most Recent Quarter 0.02
Price to Book Ratio 80.63
Industry Price to Book Ratio 7.62
Sector Price to Book Ratio 21.41
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 89.49
Sector Price to Sales Ratio Twelve Trailing Months 25.24
Analyst Buy Ratings N/A
Analyst Strong Buy Ratings N/A

Share Statistics

Total Shares Outstanding 116,848,000
Market Capitalization 183,451,360
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -14.90%
Reported EPS 12 Trailing Months -0.13
Reported EPS Past Year -0.43
Reported EPS Prior Year -0.18
Net Income Twelve Trailing Months -10,884,000
Net Income Past Year -17,691,000
Net Income Prior Year -15,397,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet

Total Cash Most Recent Quarter 1,183,000
Total Cash Past Year 1,183,000
Total Cash Prior Year 18,122,000
Net Cash Position Most Recent Quarter 1,183,000
Net Cash Position Past Year 1,183,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 5,536,000
Total Stockholder Equity Prior Year 19,571,000
Total Stockholder Equity Most Recent Quarter 5,536,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -15,404,000
Free Cash Flow Per Share Twelve Trailing Months -0.13
Free Cash Flow Past Year -15,698,000
Free Cash Flow Prior Year -19,615,000

Options

Put/Call Ratio 0.00
Has Options False
Liquidity Rating None

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.09
MACD Signal 0.05
20-Day Bollinger Lower Band 0.38
20-Day Bollinger Middle Band 1.03
20-Day Bollinger Upper Band 1.67
Beta 0.16
RSI 65.38
50-Day SMA 0.77
150-Day SMA 0.00
200-Day SMA 0.89

System

Modified 5/8/2025 11:58:11 AM EST